Randomized phase II study of IV topotecan versus CRLX101 in the second-line treatment of recurrent extensive-stage small cell lung cancer (ES-SCLC).
Thomas A. Hensing
No relevant relationships to disclose
Theodore Karrison
No relevant relationships to disclose
Edward Graeme Garmey
Employment or Leadership Position - Cerulean Pharma
Stock Ownership - Cerulean Pharma
Meliessa G. Hennessy
Employment or Leadership Position - Cerulean Pharma
Stock Ownership - Cerulean Pharma
Ravi Salgia
No relevant relationships to disclose